['psoriasis']
['msb0010841', 'msb0010841', 'msb0010841', 'msb0010841', 'placebo']

        Inclusion Criteria:

          -  Chronic plaque psoriasis for at least 6 months before screening

          -  Greater than or equal to (>=) 10% of BSA with plaques

          -  Psoriasis Area and Severity Index (PASI) >=12

          -  Static Physician's Global Assessment (sPGA) >=3 (where scores range from 0 [clear of
             disease] to 5 [severe disease]) at the screening and baseline visits

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Any condition, including protocol-specified laboratory findings and findings in the
             medical history or in the pre-trial assessments which in the Investigator's opinion
             constitutes a risk or a contraindication for the subject's participation in the trial
             or that could interfere with the trial objectives, conduct or evaluation

          -  Currently having a form of non-plaque psoriasis as specified in the protocol

          -  Drug induced psoriasis

          -  Biological treatments as specified in the protocol, within 3 months prior to Day 1

          -  Systemic immunosuppressants or phototherapy as specified in the protocol, within 1
             month prior to Day 1

          -  Use of anti-coagulant medications and/or antiplatelet medications as defined in the
             protocol

          -  Use of aspirin as defined in the protocol

          -  Topical corticosteroid treatments other than low-strength or lower-mid strength
             corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day
             1

          -  Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or IL-23
             as specified in the protocol

          -  Other protocol defined exclusion criteria could apply
      